Gilliland DG - Search Results

1

Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia.

Ballen KK, Gilliland DG, Guinan EC, Hsieh CC, Parsons SK, Rimm IJ, Ferrara JL, Bierer BE, Weinstein HJ, Antin JH. Ballen KK, et al. Among authors: gilliland dg. Bone Marrow Transplant. 1997 Nov;20(9):737-43. doi: 10.1038/sj.bmt.1700971. Bone Marrow Transplant. 1997. PMID: 9384475 Clinical Trial.

2

Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens.

Abhyankar S, Gilliland DG, Ferrara JL. Abhyankar S, et al. Among authors: gilliland dg. Transplantation. 1993 Dec;56(6):1518-23. doi: 10.1097/00007890-199312000-00045. Transplantation. 1993. PMID: 8279027

3

Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1.

Ferrara JL, Abhyankar S, Gilliland DG. Ferrara JL, et al. Among authors: gilliland dg. Transplant Proc. 1993 Feb;25(1 Pt 2):1216-7. Transplant Proc. 1993. PMID: 8442093 No abstract available.

4

Idiopathic thrombocytopenic purpura following allogeneic bone marrow transplantation--treatment with anti-D immunoglobulin.

Lee SJ, Churchill WH, Konugres A, Gilliland DG, Antin JH. Lee SJ, et al. Among authors: gilliland dg. Bone Marrow Transplant. 1997 Jan;19(2):173-4. doi: 10.1038/sj.bmt.1700634. Bone Marrow Transplant. 1997. PMID: 9116615

5

Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease.

Antin JH, Weinstein HJ, Guinan EC, McCarthy P, Bierer BE, Gilliland DG, Parsons SK, Ballen KK, Rimm IJ, Falzarano G, et al. Antin JH, et al. Among authors: gilliland dg. Blood. 1994 Aug 15;84(4):1342-8. Blood. 1994. PMID: 8049450 Free article.

6

Bone marrow dysplasia in patients with newly diagnosed acute myelogenous leukemia does not correlate with history of myelodysplasia or with remission rate and survival.

Ballen KK, Gilliland DG, Kalish LA, Shulman LN. Ballen KK, et al. Among authors: gilliland dg. Cancer. 1994 Jan 15;73(2):314-21. doi: 10.1002/1097-0142(19940115)73:2<314::aid-cncr2820730214>3.0.co;2-c. Cancer. 1994. PMID: 8293394

7

Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide.

Wheeler C, Strawderman M, Ayash L, Churchill WH, Bierer BE, Elias A, Gilliland DG, Antman K, Guinan EC, Eder JP, et al. Wheeler C, et al. Among authors: gilliland dg. J Clin Oncol. 1993 Jun;11(6):1085-91. doi: 10.1200/JCO.1993.11.6.1085. J Clin Oncol. 1993. PMID: 8099120

8

Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation.

Gilliland DG, Gribben JG. Gilliland DG, et al. Biol Blood Marrow Transplant. 2002;8(1):9-16. doi: 10.1053/bbmt.2002.v8.pm11846355. Biol Blood Marrow Transplant. 2002. PMID: 11846355 Free article. Review.

9

Prediction of therapy-related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma.

Legare RD, Gribben JG, Maragh M, Hermanowski-Vosatka A, Roach S, Tantravahi R, Nadler LM, Gilliland DG. Legare RD, et al. Among authors: gilliland dg. Am J Hematol. 1997 Sep;56(1):45-51. doi: 10.1002/(sici)1096-8652(199709)56:1<45::aid-ajh10>3.0.co;2-1. Am J Hematol. 1997. PMID: 9298868 Free article.

10

Clonality in juvenile chronic myelogenous leukemia.

Busque L, Gilliland DG, Prchal JT, Sieff CA, Weinstein HJ, Sokol JM, Belickova M, Wayne AS, Zuckerman KS, Sokol L, et al. Busque L, et al. Among authors: gilliland dg. Blood. 1995 Jan 1;85(1):21-30. Blood. 1995. PMID: 7803795 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

275 results

Search Page

Filters